OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
News|Articles|April 1, 2002
- Pharmaceutical Technology-04-02-2002
- Volume 26
- Issue 4
Outsourcing Outlook
Author(s)Jim Miller
The author discusses the current soft demand and excess capacity in the contract-manufacturing market of small molecule actives and intermediates.
Advertisement
Articles in this issue
over 24 years ago
The Usefulness of 0.45 µm–Rated Filter Membranesover 24 years ago
Monitoring Blend Uniformity with Effusivityover 24 years ago
Bush Budget Combats Bioterrorism, Promotes Drug Safetyover 24 years ago
Liposomes: A ReviewAdvertisement
Related to this article
Roche-Hansoh, Merck KGaA-Silence, and Lilly-METiS deals show how ADCs, siRNA, and lipid nanoparticles reshape demands on CMC and manufacturing teams.
Germany is home to several prominent pharma companies and more than 1000 innovative biotechs.
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
2
Germany’s Medical Biotechnology Sector is Flourishing
3
PharmTech AI Pulse Check: Why Pharma Should Weigh In on FDA's Generative AI Paper
4
Sustainability in Healthcare Packaging: The Journey From Yesterday to Tomorrow
5